As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Taking a page from Eli Lilly and their LillyDirect online pharmacy ... Lilly’s Next-Generation Triple Agonist GLP-1 Drug Looks Very Promising Lilly has also been working on their next-generation ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the ... drugs like Ozempic and Wegovy, as well as Eli Lilly’s tirzepatide-based Mounjaro and ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Biolexis Therapeutics has achieved a transformative milestone in metabolic drug discovery with the successful resolution of ...